Chesapeake Capital Corp IL Grows Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

Chesapeake Capital Corp IL raised its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 27.9% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 6,176 shares of the company’s stock after buying an additional 1,347 shares during the period. Chesapeake Capital Corp IL’s holdings in Twist Bioscience were worth $287,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Signaturefd LLC raised its stake in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after buying an additional 306 shares during the last quarter. EdgeRock Capital LLC purchased a new position in shares of Twist Bioscience during the 2nd quarter valued at about $43,000. Blue Trust Inc. raised its stake in shares of Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after buying an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new position in shares of Twist Bioscience during the 2nd quarter valued at about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after purchasing an additional 381 shares in the last quarter.

Twist Bioscience Trading Down 5.3 %

NASDAQ:TWST opened at $36.89 on Monday. Twist Bioscience Co. has a 12 month low of $18.80 and a 12 month high of $60.90. The stock has a 50 day moving average of $43.90 and a two-hundred day moving average of $46.11. The firm has a market cap of $2.16 billion, a P/E ratio of -9.66 and a beta of 1.78.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Evercore ISI lifted their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Leerink Partners lifted their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. lifted their price target on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Robert W. Baird lifted their price target on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. Finally, Barclays cut their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $51.22.

Insiders Place Their Bets

In other news, SVP Paula Green sold 1,057 shares of the company’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $41.56, for a total value of $43,928.92. Following the completion of the sale, the senior vice president now directly owns 121,013 shares in the company, valued at $5,029,300.28. This represents a 0.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Emily M. Leproust sold 14,334 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $639,296.40. Following the completion of the sale, the chief executive officer now owns 589,552 shares of the company’s stock, valued at $26,294,019.20. This trade represents a 2.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 98,118 shares of company stock worth $4,391,151. Corporate insiders own 3.92% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.